Global Cholesterol Lowering Agents Market

Cholesterol Lowering Agents Comprehensive Study by Type (Statins and Combination, PCSK9 Inhibitors, Bile Acid Sequestrants, Fibrates, Cholesterol Absorption Inhibitors, Others), Application (Hospital, Household, Other), Indication (Hypercholesterolemia, Coronary Artery Disease, Higher Triglycerides), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Players and Region - Global Market Outlook to 2028

Cholesterol Lowering Agents Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Cholesterol Lowering Agents Market Overview:
Cholesterol is a fat found in the blood. It’s produced by the liver and found in foods from animal sources, such as meat, poultry, and full-fat dairy products. The body needs some cholesterol to ensure organs grow and function properly. However, too much cholesterol in the blood can clog the arteries and lead to serious health conditions. Cholesterol lowering agents decrease the production of cholesterol in the liver and help remove excess cholesterol from the blood vessels.

AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Historical Period2018-2022
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Raising health awareness is supporting the growth of cholesterol-lowering agents on a global level and The shift of food preferences and choice of a healthy lifestyle amongst the wide population of people

Market Growth Drivers:
The increasing cases of mortality rate due to cardiovascular diseases and The health benefits obtained from the cholesterol-lowering agents

Challenges:
The stringent government regulation

Restraints:
The cost of the products

Opportunities:
Increasing healthcare expenditure in developing and developed countries

Competitive Landscape:
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Pfizer Inc. (United States), Sanofi (France), GlaxoSmithKline plc (United Kingdom), Novartis AG (Switzerland), Merck & Co., Inc. (United States), Amgen, Inc. (United States), Takeda Pharmaceutical Company Limited (Japan), Sun Pharmaceutical Industries Ltd. (India), AbbVie, Inc. (United States) and Mylan N.V. (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Cholesterol Lowering Agents market by 2028. Considering Market by Indication, the sub-segment i.e. Hypercholesterolemia will boost the Cholesterol Lowering Agents market. Considering Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Cholesterol Lowering Agents market.

In 2020, Bempedoic acid has been certified by the FDA to assist reduce LDL cholesterol in people with heterozygous familial hypercholesterolemia or existing atherosclerotic cardiovascular disease for whom statins are ineffective. The first in its class, an oral ATP citrate lyase inhibitor, works by lowering cholesterol production and increasing LDL receptors.

What Can be Explored with the Cholesterol Lowering Agents Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Cholesterol Lowering Agents Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Cholesterol Lowering Agents
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Cholesterol Lowering Agents market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Cholesterol Lowering Agents market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Cholesterol-lowering agents manufacturers, Heath sectors, Food and Nutrition products manufacturers, Retailers and wholesalers and Traders, importers, and exporters.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Statins and Combination
  • PCSK9 Inhibitors
  • Bile Acid Sequestrants
  • Fibrates
  • Cholesterol Absorption Inhibitors
  • Others
By Application
  • Hospital
  • Household
  • Other
By Indication
  • Hypercholesterolemia
  • Coronary Artery Disease
  • Higher Triglycerides

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The increasing cases of mortality rate due to cardiovascular diseases
      • 3.2.2. The health benefits obtained from the cholesterol-lowering agents
    • 3.3. Market Challenges
      • 3.3.1. The stringent government regulation
    • 3.4. Market Trends
      • 3.4.1. Raising health awareness is supporting the growth of cholesterol-lowering agents on a global level
      • 3.4.2. The shift of food preferences and choice of a healthy lifestyle amongst the wide population of people
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cholesterol Lowering Agents, by Type, Application, Indication, Distribution Channel and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Cholesterol Lowering Agents (Value)
      • 5.2.1. Global Cholesterol Lowering Agents by: Type (Value)
        • 5.2.1.1. Statins and Combination
        • 5.2.1.2. PCSK9 Inhibitors
        • 5.2.1.3. Bile Acid Sequestrants
        • 5.2.1.4. Fibrates
        • 5.2.1.5. Cholesterol Absorption Inhibitors
        • 5.2.1.6. Others
      • 5.2.2. Global Cholesterol Lowering Agents by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Household
        • 5.2.2.3. Other
      • 5.2.3. Global Cholesterol Lowering Agents by: Indication (Value)
        • 5.2.3.1. Hypercholesterolemia
        • 5.2.3.2. Coronary Artery Disease
        • 5.2.3.3. Higher Triglycerides
      • 5.2.4. Global Cholesterol Lowering Agents by: Distribution Channel (Value)
        • 5.2.4.1. Hospital Pharmacies
        • 5.2.4.2. Retail Pharmacies
        • 5.2.4.3. Online Pharmacies
      • 5.2.5. Global Cholesterol Lowering Agents Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Cholesterol Lowering Agents: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sanofi (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GlaxoSmithKline plc (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Novartis AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Merck & Co., Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Amgen, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Takeda Pharmaceutical Company Limited (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sun Pharmaceutical Industries Ltd. (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. AbbVie, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Mylan N.V. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Cholesterol Lowering Agents Sale, by Type, Application, Indication, Distribution Channel and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Cholesterol Lowering Agents (Value)
      • 7.2.1. Global Cholesterol Lowering Agents by: Type (Value)
        • 7.2.1.1. Statins and Combination
        • 7.2.1.2. PCSK9 Inhibitors
        • 7.2.1.3. Bile Acid Sequestrants
        • 7.2.1.4. Fibrates
        • 7.2.1.5. Cholesterol Absorption Inhibitors
        • 7.2.1.6. Others
      • 7.2.2. Global Cholesterol Lowering Agents by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Household
        • 7.2.2.3. Other
      • 7.2.3. Global Cholesterol Lowering Agents by: Indication (Value)
        • 7.2.3.1. Hypercholesterolemia
        • 7.2.3.2. Coronary Artery Disease
        • 7.2.3.3. Higher Triglycerides
      • 7.2.4. Global Cholesterol Lowering Agents by: Distribution Channel (Value)
        • 7.2.4.1. Hospital Pharmacies
        • 7.2.4.2. Retail Pharmacies
        • 7.2.4.3. Online Pharmacies
      • 7.2.5. Global Cholesterol Lowering Agents Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cholesterol Lowering Agents: by Type(USD Million)
  • Table 2. Cholesterol Lowering Agents Statins and Combination , by Region USD Million (2017-2022)
  • Table 3. Cholesterol Lowering Agents PCSK9 Inhibitors , by Region USD Million (2017-2022)
  • Table 4. Cholesterol Lowering Agents Bile Acid Sequestrants , by Region USD Million (2017-2022)
  • Table 5. Cholesterol Lowering Agents Fibrates , by Region USD Million (2017-2022)
  • Table 6. Cholesterol Lowering Agents Cholesterol Absorption Inhibitors , by Region USD Million (2017-2022)
  • Table 7. Cholesterol Lowering Agents Others , by Region USD Million (2017-2022)
  • Table 8. Cholesterol Lowering Agents: by Application(USD Million)
  • Table 9. Cholesterol Lowering Agents Hospital , by Region USD Million (2017-2022)
  • Table 10. Cholesterol Lowering Agents Household , by Region USD Million (2017-2022)
  • Table 11. Cholesterol Lowering Agents Other , by Region USD Million (2017-2022)
  • Table 12. Cholesterol Lowering Agents: by Indication(USD Million)
  • Table 13. Cholesterol Lowering Agents Hypercholesterolemia , by Region USD Million (2017-2022)
  • Table 14. Cholesterol Lowering Agents Coronary Artery Disease , by Region USD Million (2017-2022)
  • Table 15. Cholesterol Lowering Agents Higher Triglycerides , by Region USD Million (2017-2022)
  • Table 16. Cholesterol Lowering Agents: by Distribution Channel(USD Million)
  • Table 17. Cholesterol Lowering Agents Hospital Pharmacies , by Region USD Million (2017-2022)
  • Table 18. Cholesterol Lowering Agents Retail Pharmacies , by Region USD Million (2017-2022)
  • Table 19. Cholesterol Lowering Agents Online Pharmacies , by Region USD Million (2017-2022)
  • Table 20. South America Cholesterol Lowering Agents, by Country USD Million (2017-2022)
  • Table 21. South America Cholesterol Lowering Agents, by Type USD Million (2017-2022)
  • Table 22. South America Cholesterol Lowering Agents, by Application USD Million (2017-2022)
  • Table 23. South America Cholesterol Lowering Agents, by Indication USD Million (2017-2022)
  • Table 24. South America Cholesterol Lowering Agents, by Distribution Channel USD Million (2017-2022)
  • Table 25. Brazil Cholesterol Lowering Agents, by Type USD Million (2017-2022)
  • Table 26. Brazil Cholesterol Lowering Agents, by Application USD Million (2017-2022)
  • Table 27. Brazil Cholesterol Lowering Agents, by Indication USD Million (2017-2022)
  • Table 28. Brazil Cholesterol Lowering Agents, by Distribution Channel USD Million (2017-2022)
  • Table 29. Argentina Cholesterol Lowering Agents, by Type USD Million (2017-2022)
  • Table 30. Argentina Cholesterol Lowering Agents, by Application USD Million (2017-2022)
  • Table 31. Argentina Cholesterol Lowering Agents, by Indication USD Million (2017-2022)
  • Table 32. Argentina Cholesterol Lowering Agents, by Distribution Channel USD Million (2017-2022)
  • Table 33. Rest of South America Cholesterol Lowering Agents, by Type USD Million (2017-2022)
  • Table 34. Rest of South America Cholesterol Lowering Agents, by Application USD Million (2017-2022)
  • Table 35. Rest of South America Cholesterol Lowering Agents, by Indication USD Million (2017-2022)
  • Table 36. Rest of South America Cholesterol Lowering Agents, by Distribution Channel USD Million (2017-2022)
  • Table 37. Asia Pacific Cholesterol Lowering Agents, by Country USD Million (2017-2022)
  • Table 38. Asia Pacific Cholesterol Lowering Agents, by Type USD Million (2017-2022)
  • Table 39. Asia Pacific Cholesterol Lowering Agents, by Application USD Million (2017-2022)
  • Table 40. Asia Pacific Cholesterol Lowering Agents, by Indication USD Million (2017-2022)
  • Table 41. Asia Pacific Cholesterol Lowering Agents, by Distribution Channel USD Million (2017-2022)
  • Table 42. China Cholesterol Lowering Agents, by Type USD Million (2017-2022)
  • Table 43. China Cholesterol Lowering Agents, by Application USD Million (2017-2022)
  • Table 44. China Cholesterol Lowering Agents, by Indication USD Million (2017-2022)
  • Table 45. China Cholesterol Lowering Agents, by Distribution Channel USD Million (2017-2022)
  • Table 46. Japan Cholesterol Lowering Agents, by Type USD Million (2017-2022)
  • Table 47. Japan Cholesterol Lowering Agents, by Application USD Million (2017-2022)
  • Table 48. Japan Cholesterol Lowering Agents, by Indication USD Million (2017-2022)
  • Table 49. Japan Cholesterol Lowering Agents, by Distribution Channel USD Million (2017-2022)
  • Table 50. India Cholesterol Lowering Agents, by Type USD Million (2017-2022)
  • Table 51. India Cholesterol Lowering Agents, by Application USD Million (2017-2022)
  • Table 52. India Cholesterol Lowering Agents, by Indication USD Million (2017-2022)
  • Table 53. India Cholesterol Lowering Agents, by Distribution Channel USD Million (2017-2022)
  • Table 54. South Korea Cholesterol Lowering Agents, by Type USD Million (2017-2022)
  • Table 55. South Korea Cholesterol Lowering Agents, by Application USD Million (2017-2022)
  • Table 56. South Korea Cholesterol Lowering Agents, by Indication USD Million (2017-2022)
  • Table 57. South Korea Cholesterol Lowering Agents, by Distribution Channel USD Million (2017-2022)
  • Table 58. Taiwan Cholesterol Lowering Agents, by Type USD Million (2017-2022)
  • Table 59. Taiwan Cholesterol Lowering Agents, by Application USD Million (2017-2022)
  • Table 60. Taiwan Cholesterol Lowering Agents, by Indication USD Million (2017-2022)
  • Table 61. Taiwan Cholesterol Lowering Agents, by Distribution Channel USD Million (2017-2022)
  • Table 62. Australia Cholesterol Lowering Agents, by Type USD Million (2017-2022)
  • Table 63. Australia Cholesterol Lowering Agents, by Application USD Million (2017-2022)
  • Table 64. Australia Cholesterol Lowering Agents, by Indication USD Million (2017-2022)
  • Table 65. Australia Cholesterol Lowering Agents, by Distribution Channel USD Million (2017-2022)
  • Table 66. Rest of Asia-Pacific Cholesterol Lowering Agents, by Type USD Million (2017-2022)
  • Table 67. Rest of Asia-Pacific Cholesterol Lowering Agents, by Application USD Million (2017-2022)
  • Table 68. Rest of Asia-Pacific Cholesterol Lowering Agents, by Indication USD Million (2017-2022)
  • Table 69. Rest of Asia-Pacific Cholesterol Lowering Agents, by Distribution Channel USD Million (2017-2022)
  • Table 70. Europe Cholesterol Lowering Agents, by Country USD Million (2017-2022)
  • Table 71. Europe Cholesterol Lowering Agents, by Type USD Million (2017-2022)
  • Table 72. Europe Cholesterol Lowering Agents, by Application USD Million (2017-2022)
  • Table 73. Europe Cholesterol Lowering Agents, by Indication USD Million (2017-2022)
  • Table 74. Europe Cholesterol Lowering Agents, by Distribution Channel USD Million (2017-2022)
  • Table 75. Germany Cholesterol Lowering Agents, by Type USD Million (2017-2022)
  • Table 76. Germany Cholesterol Lowering Agents, by Application USD Million (2017-2022)
  • Table 77. Germany Cholesterol Lowering Agents, by Indication USD Million (2017-2022)
  • Table 78. Germany Cholesterol Lowering Agents, by Distribution Channel USD Million (2017-2022)
  • Table 79. France Cholesterol Lowering Agents, by Type USD Million (2017-2022)
  • Table 80. France Cholesterol Lowering Agents, by Application USD Million (2017-2022)
  • Table 81. France Cholesterol Lowering Agents, by Indication USD Million (2017-2022)
  • Table 82. France Cholesterol Lowering Agents, by Distribution Channel USD Million (2017-2022)
  • Table 83. Italy Cholesterol Lowering Agents, by Type USD Million (2017-2022)
  • Table 84. Italy Cholesterol Lowering Agents, by Application USD Million (2017-2022)
  • Table 85. Italy Cholesterol Lowering Agents, by Indication USD Million (2017-2022)
  • Table 86. Italy Cholesterol Lowering Agents, by Distribution Channel USD Million (2017-2022)
  • Table 87. United Kingdom Cholesterol Lowering Agents, by Type USD Million (2017-2022)
  • Table 88. United Kingdom Cholesterol Lowering Agents, by Application USD Million (2017-2022)
  • Table 89. United Kingdom Cholesterol Lowering Agents, by Indication USD Million (2017-2022)
  • Table 90. United Kingdom Cholesterol Lowering Agents, by Distribution Channel USD Million (2017-2022)
  • Table 91. Netherlands Cholesterol Lowering Agents, by Type USD Million (2017-2022)
  • Table 92. Netherlands Cholesterol Lowering Agents, by Application USD Million (2017-2022)
  • Table 93. Netherlands Cholesterol Lowering Agents, by Indication USD Million (2017-2022)
  • Table 94. Netherlands Cholesterol Lowering Agents, by Distribution Channel USD Million (2017-2022)
  • Table 95. Rest of Europe Cholesterol Lowering Agents, by Type USD Million (2017-2022)
  • Table 96. Rest of Europe Cholesterol Lowering Agents, by Application USD Million (2017-2022)
  • Table 97. Rest of Europe Cholesterol Lowering Agents, by Indication USD Million (2017-2022)
  • Table 98. Rest of Europe Cholesterol Lowering Agents, by Distribution Channel USD Million (2017-2022)
  • Table 99. MEA Cholesterol Lowering Agents, by Country USD Million (2017-2022)
  • Table 100. MEA Cholesterol Lowering Agents, by Type USD Million (2017-2022)
  • Table 101. MEA Cholesterol Lowering Agents, by Application USD Million (2017-2022)
  • Table 102. MEA Cholesterol Lowering Agents, by Indication USD Million (2017-2022)
  • Table 103. MEA Cholesterol Lowering Agents, by Distribution Channel USD Million (2017-2022)
  • Table 104. Middle East Cholesterol Lowering Agents, by Type USD Million (2017-2022)
  • Table 105. Middle East Cholesterol Lowering Agents, by Application USD Million (2017-2022)
  • Table 106. Middle East Cholesterol Lowering Agents, by Indication USD Million (2017-2022)
  • Table 107. Middle East Cholesterol Lowering Agents, by Distribution Channel USD Million (2017-2022)
  • Table 108. Africa Cholesterol Lowering Agents, by Type USD Million (2017-2022)
  • Table 109. Africa Cholesterol Lowering Agents, by Application USD Million (2017-2022)
  • Table 110. Africa Cholesterol Lowering Agents, by Indication USD Million (2017-2022)
  • Table 111. Africa Cholesterol Lowering Agents, by Distribution Channel USD Million (2017-2022)
  • Table 112. North America Cholesterol Lowering Agents, by Country USD Million (2017-2022)
  • Table 113. North America Cholesterol Lowering Agents, by Type USD Million (2017-2022)
  • Table 114. North America Cholesterol Lowering Agents, by Application USD Million (2017-2022)
  • Table 115. North America Cholesterol Lowering Agents, by Indication USD Million (2017-2022)
  • Table 116. North America Cholesterol Lowering Agents, by Distribution Channel USD Million (2017-2022)
  • Table 117. United States Cholesterol Lowering Agents, by Type USD Million (2017-2022)
  • Table 118. United States Cholesterol Lowering Agents, by Application USD Million (2017-2022)
  • Table 119. United States Cholesterol Lowering Agents, by Indication USD Million (2017-2022)
  • Table 120. United States Cholesterol Lowering Agents, by Distribution Channel USD Million (2017-2022)
  • Table 121. Canada Cholesterol Lowering Agents, by Type USD Million (2017-2022)
  • Table 122. Canada Cholesterol Lowering Agents, by Application USD Million (2017-2022)
  • Table 123. Canada Cholesterol Lowering Agents, by Indication USD Million (2017-2022)
  • Table 124. Canada Cholesterol Lowering Agents, by Distribution Channel USD Million (2017-2022)
  • Table 125. Mexico Cholesterol Lowering Agents, by Type USD Million (2017-2022)
  • Table 126. Mexico Cholesterol Lowering Agents, by Application USD Million (2017-2022)
  • Table 127. Mexico Cholesterol Lowering Agents, by Indication USD Million (2017-2022)
  • Table 128. Mexico Cholesterol Lowering Agents, by Distribution Channel USD Million (2017-2022)
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Cholesterol Lowering Agents: by Type(USD Million)
  • Table 140. Cholesterol Lowering Agents Statins and Combination , by Region USD Million (2023-2028)
  • Table 141. Cholesterol Lowering Agents PCSK9 Inhibitors , by Region USD Million (2023-2028)
  • Table 142. Cholesterol Lowering Agents Bile Acid Sequestrants , by Region USD Million (2023-2028)
  • Table 143. Cholesterol Lowering Agents Fibrates , by Region USD Million (2023-2028)
  • Table 144. Cholesterol Lowering Agents Cholesterol Absorption Inhibitors , by Region USD Million (2023-2028)
  • Table 145. Cholesterol Lowering Agents Others , by Region USD Million (2023-2028)
  • Table 146. Cholesterol Lowering Agents: by Application(USD Million)
  • Table 147. Cholesterol Lowering Agents Hospital , by Region USD Million (2023-2028)
  • Table 148. Cholesterol Lowering Agents Household , by Region USD Million (2023-2028)
  • Table 149. Cholesterol Lowering Agents Other , by Region USD Million (2023-2028)
  • Table 150. Cholesterol Lowering Agents: by Indication(USD Million)
  • Table 151. Cholesterol Lowering Agents Hypercholesterolemia , by Region USD Million (2023-2028)
  • Table 152. Cholesterol Lowering Agents Coronary Artery Disease , by Region USD Million (2023-2028)
  • Table 153. Cholesterol Lowering Agents Higher Triglycerides , by Region USD Million (2023-2028)
  • Table 154. Cholesterol Lowering Agents: by Distribution Channel(USD Million)
  • Table 155. Cholesterol Lowering Agents Hospital Pharmacies , by Region USD Million (2023-2028)
  • Table 156. Cholesterol Lowering Agents Retail Pharmacies , by Region USD Million (2023-2028)
  • Table 157. Cholesterol Lowering Agents Online Pharmacies , by Region USD Million (2023-2028)
  • Table 158. South America Cholesterol Lowering Agents, by Country USD Million (2023-2028)
  • Table 159. South America Cholesterol Lowering Agents, by Type USD Million (2023-2028)
  • Table 160. South America Cholesterol Lowering Agents, by Application USD Million (2023-2028)
  • Table 161. South America Cholesterol Lowering Agents, by Indication USD Million (2023-2028)
  • Table 162. South America Cholesterol Lowering Agents, by Distribution Channel USD Million (2023-2028)
  • Table 163. Brazil Cholesterol Lowering Agents, by Type USD Million (2023-2028)
  • Table 164. Brazil Cholesterol Lowering Agents, by Application USD Million (2023-2028)
  • Table 165. Brazil Cholesterol Lowering Agents, by Indication USD Million (2023-2028)
  • Table 166. Brazil Cholesterol Lowering Agents, by Distribution Channel USD Million (2023-2028)
  • Table 167. Argentina Cholesterol Lowering Agents, by Type USD Million (2023-2028)
  • Table 168. Argentina Cholesterol Lowering Agents, by Application USD Million (2023-2028)
  • Table 169. Argentina Cholesterol Lowering Agents, by Indication USD Million (2023-2028)
  • Table 170. Argentina Cholesterol Lowering Agents, by Distribution Channel USD Million (2023-2028)
  • Table 171. Rest of South America Cholesterol Lowering Agents, by Type USD Million (2023-2028)
  • Table 172. Rest of South America Cholesterol Lowering Agents, by Application USD Million (2023-2028)
  • Table 173. Rest of South America Cholesterol Lowering Agents, by Indication USD Million (2023-2028)
  • Table 174. Rest of South America Cholesterol Lowering Agents, by Distribution Channel USD Million (2023-2028)
  • Table 175. Asia Pacific Cholesterol Lowering Agents, by Country USD Million (2023-2028)
  • Table 176. Asia Pacific Cholesterol Lowering Agents, by Type USD Million (2023-2028)
  • Table 177. Asia Pacific Cholesterol Lowering Agents, by Application USD Million (2023-2028)
  • Table 178. Asia Pacific Cholesterol Lowering Agents, by Indication USD Million (2023-2028)
  • Table 179. Asia Pacific Cholesterol Lowering Agents, by Distribution Channel USD Million (2023-2028)
  • Table 180. China Cholesterol Lowering Agents, by Type USD Million (2023-2028)
  • Table 181. China Cholesterol Lowering Agents, by Application USD Million (2023-2028)
  • Table 182. China Cholesterol Lowering Agents, by Indication USD Million (2023-2028)
  • Table 183. China Cholesterol Lowering Agents, by Distribution Channel USD Million (2023-2028)
  • Table 184. Japan Cholesterol Lowering Agents, by Type USD Million (2023-2028)
  • Table 185. Japan Cholesterol Lowering Agents, by Application USD Million (2023-2028)
  • Table 186. Japan Cholesterol Lowering Agents, by Indication USD Million (2023-2028)
  • Table 187. Japan Cholesterol Lowering Agents, by Distribution Channel USD Million (2023-2028)
  • Table 188. India Cholesterol Lowering Agents, by Type USD Million (2023-2028)
  • Table 189. India Cholesterol Lowering Agents, by Application USD Million (2023-2028)
  • Table 190. India Cholesterol Lowering Agents, by Indication USD Million (2023-2028)
  • Table 191. India Cholesterol Lowering Agents, by Distribution Channel USD Million (2023-2028)
  • Table 192. South Korea Cholesterol Lowering Agents, by Type USD Million (2023-2028)
  • Table 193. South Korea Cholesterol Lowering Agents, by Application USD Million (2023-2028)
  • Table 194. South Korea Cholesterol Lowering Agents, by Indication USD Million (2023-2028)
  • Table 195. South Korea Cholesterol Lowering Agents, by Distribution Channel USD Million (2023-2028)
  • Table 196. Taiwan Cholesterol Lowering Agents, by Type USD Million (2023-2028)
  • Table 197. Taiwan Cholesterol Lowering Agents, by Application USD Million (2023-2028)
  • Table 198. Taiwan Cholesterol Lowering Agents, by Indication USD Million (2023-2028)
  • Table 199. Taiwan Cholesterol Lowering Agents, by Distribution Channel USD Million (2023-2028)
  • Table 200. Australia Cholesterol Lowering Agents, by Type USD Million (2023-2028)
  • Table 201. Australia Cholesterol Lowering Agents, by Application USD Million (2023-2028)
  • Table 202. Australia Cholesterol Lowering Agents, by Indication USD Million (2023-2028)
  • Table 203. Australia Cholesterol Lowering Agents, by Distribution Channel USD Million (2023-2028)
  • Table 204. Rest of Asia-Pacific Cholesterol Lowering Agents, by Type USD Million (2023-2028)
  • Table 205. Rest of Asia-Pacific Cholesterol Lowering Agents, by Application USD Million (2023-2028)
  • Table 206. Rest of Asia-Pacific Cholesterol Lowering Agents, by Indication USD Million (2023-2028)
  • Table 207. Rest of Asia-Pacific Cholesterol Lowering Agents, by Distribution Channel USD Million (2023-2028)
  • Table 208. Europe Cholesterol Lowering Agents, by Country USD Million (2023-2028)
  • Table 209. Europe Cholesterol Lowering Agents, by Type USD Million (2023-2028)
  • Table 210. Europe Cholesterol Lowering Agents, by Application USD Million (2023-2028)
  • Table 211. Europe Cholesterol Lowering Agents, by Indication USD Million (2023-2028)
  • Table 212. Europe Cholesterol Lowering Agents, by Distribution Channel USD Million (2023-2028)
  • Table 213. Germany Cholesterol Lowering Agents, by Type USD Million (2023-2028)
  • Table 214. Germany Cholesterol Lowering Agents, by Application USD Million (2023-2028)
  • Table 215. Germany Cholesterol Lowering Agents, by Indication USD Million (2023-2028)
  • Table 216. Germany Cholesterol Lowering Agents, by Distribution Channel USD Million (2023-2028)
  • Table 217. France Cholesterol Lowering Agents, by Type USD Million (2023-2028)
  • Table 218. France Cholesterol Lowering Agents, by Application USD Million (2023-2028)
  • Table 219. France Cholesterol Lowering Agents, by Indication USD Million (2023-2028)
  • Table 220. France Cholesterol Lowering Agents, by Distribution Channel USD Million (2023-2028)
  • Table 221. Italy Cholesterol Lowering Agents, by Type USD Million (2023-2028)
  • Table 222. Italy Cholesterol Lowering Agents, by Application USD Million (2023-2028)
  • Table 223. Italy Cholesterol Lowering Agents, by Indication USD Million (2023-2028)
  • Table 224. Italy Cholesterol Lowering Agents, by Distribution Channel USD Million (2023-2028)
  • Table 225. United Kingdom Cholesterol Lowering Agents, by Type USD Million (2023-2028)
  • Table 226. United Kingdom Cholesterol Lowering Agents, by Application USD Million (2023-2028)
  • Table 227. United Kingdom Cholesterol Lowering Agents, by Indication USD Million (2023-2028)
  • Table 228. United Kingdom Cholesterol Lowering Agents, by Distribution Channel USD Million (2023-2028)
  • Table 229. Netherlands Cholesterol Lowering Agents, by Type USD Million (2023-2028)
  • Table 230. Netherlands Cholesterol Lowering Agents, by Application USD Million (2023-2028)
  • Table 231. Netherlands Cholesterol Lowering Agents, by Indication USD Million (2023-2028)
  • Table 232. Netherlands Cholesterol Lowering Agents, by Distribution Channel USD Million (2023-2028)
  • Table 233. Rest of Europe Cholesterol Lowering Agents, by Type USD Million (2023-2028)
  • Table 234. Rest of Europe Cholesterol Lowering Agents, by Application USD Million (2023-2028)
  • Table 235. Rest of Europe Cholesterol Lowering Agents, by Indication USD Million (2023-2028)
  • Table 236. Rest of Europe Cholesterol Lowering Agents, by Distribution Channel USD Million (2023-2028)
  • Table 237. MEA Cholesterol Lowering Agents, by Country USD Million (2023-2028)
  • Table 238. MEA Cholesterol Lowering Agents, by Type USD Million (2023-2028)
  • Table 239. MEA Cholesterol Lowering Agents, by Application USD Million (2023-2028)
  • Table 240. MEA Cholesterol Lowering Agents, by Indication USD Million (2023-2028)
  • Table 241. MEA Cholesterol Lowering Agents, by Distribution Channel USD Million (2023-2028)
  • Table 242. Middle East Cholesterol Lowering Agents, by Type USD Million (2023-2028)
  • Table 243. Middle East Cholesterol Lowering Agents, by Application USD Million (2023-2028)
  • Table 244. Middle East Cholesterol Lowering Agents, by Indication USD Million (2023-2028)
  • Table 245. Middle East Cholesterol Lowering Agents, by Distribution Channel USD Million (2023-2028)
  • Table 246. Africa Cholesterol Lowering Agents, by Type USD Million (2023-2028)
  • Table 247. Africa Cholesterol Lowering Agents, by Application USD Million (2023-2028)
  • Table 248. Africa Cholesterol Lowering Agents, by Indication USD Million (2023-2028)
  • Table 249. Africa Cholesterol Lowering Agents, by Distribution Channel USD Million (2023-2028)
  • Table 250. North America Cholesterol Lowering Agents, by Country USD Million (2023-2028)
  • Table 251. North America Cholesterol Lowering Agents, by Type USD Million (2023-2028)
  • Table 252. North America Cholesterol Lowering Agents, by Application USD Million (2023-2028)
  • Table 253. North America Cholesterol Lowering Agents, by Indication USD Million (2023-2028)
  • Table 254. North America Cholesterol Lowering Agents, by Distribution Channel USD Million (2023-2028)
  • Table 255. United States Cholesterol Lowering Agents, by Type USD Million (2023-2028)
  • Table 256. United States Cholesterol Lowering Agents, by Application USD Million (2023-2028)
  • Table 257. United States Cholesterol Lowering Agents, by Indication USD Million (2023-2028)
  • Table 258. United States Cholesterol Lowering Agents, by Distribution Channel USD Million (2023-2028)
  • Table 259. Canada Cholesterol Lowering Agents, by Type USD Million (2023-2028)
  • Table 260. Canada Cholesterol Lowering Agents, by Application USD Million (2023-2028)
  • Table 261. Canada Cholesterol Lowering Agents, by Indication USD Million (2023-2028)
  • Table 262. Canada Cholesterol Lowering Agents, by Distribution Channel USD Million (2023-2028)
  • Table 263. Mexico Cholesterol Lowering Agents, by Type USD Million (2023-2028)
  • Table 264. Mexico Cholesterol Lowering Agents, by Application USD Million (2023-2028)
  • Table 265. Mexico Cholesterol Lowering Agents, by Indication USD Million (2023-2028)
  • Table 266. Mexico Cholesterol Lowering Agents, by Distribution Channel USD Million (2023-2028)
  • Table 267. Research Programs/Design for This Report
  • Table 268. Key Data Information from Secondary Sources
  • Table 269. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cholesterol Lowering Agents: by Type USD Million (2017-2022)
  • Figure 5. Global Cholesterol Lowering Agents: by Application USD Million (2017-2022)
  • Figure 6. Global Cholesterol Lowering Agents: by Indication USD Million (2017-2022)
  • Figure 7. Global Cholesterol Lowering Agents: by Distribution Channel USD Million (2017-2022)
  • Figure 8. South America Cholesterol Lowering Agents Share (%), by Country
  • Figure 9. Asia Pacific Cholesterol Lowering Agents Share (%), by Country
  • Figure 10. Europe Cholesterol Lowering Agents Share (%), by Country
  • Figure 11. MEA Cholesterol Lowering Agents Share (%), by Country
  • Figure 12. North America Cholesterol Lowering Agents Share (%), by Country
  • Figure 13. Global Cholesterol Lowering Agents share by Players 2022 (%)
  • Figure 14. Global Cholesterol Lowering Agents share by Players (Top 3) 2022(%)
  • Figure 15. Global Cholesterol Lowering Agents share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Pfizer Inc. (United States) Revenue: by Geography 2022
  • Figure 19. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 20. Sanofi (France) Revenue: by Geography 2022
  • Figure 21. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 22. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2022
  • Figure 23. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. Novartis AG (Switzerland) Revenue: by Geography 2022
  • Figure 25. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Merck & Co., Inc. (United States) Revenue: by Geography 2022
  • Figure 27. Amgen, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Amgen, Inc. (United States) Revenue: by Geography 2022
  • Figure 29. Takeda Pharmaceutical Company Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 30. Takeda Pharmaceutical Company Limited (Japan) Revenue: by Geography 2022
  • Figure 31. Sun Pharmaceutical Industries Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 32. Sun Pharmaceutical Industries Ltd. (India) Revenue: by Geography 2022
  • Figure 33. AbbVie, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. AbbVie, Inc. (United States) Revenue: by Geography 2022
  • Figure 35. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Mylan N.V. (United States) Revenue: by Geography 2022
  • Figure 37. Global Cholesterol Lowering Agents: by Type USD Million (2023-2028)
  • Figure 38. Global Cholesterol Lowering Agents: by Application USD Million (2023-2028)
  • Figure 39. Global Cholesterol Lowering Agents: by Indication USD Million (2023-2028)
  • Figure 40. Global Cholesterol Lowering Agents: by Distribution Channel USD Million (2023-2028)
  • Figure 41. South America Cholesterol Lowering Agents Share (%), by Country
  • Figure 42. Asia Pacific Cholesterol Lowering Agents Share (%), by Country
  • Figure 43. Europe Cholesterol Lowering Agents Share (%), by Country
  • Figure 44. MEA Cholesterol Lowering Agents Share (%), by Country
  • Figure 45. North America Cholesterol Lowering Agents Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Pfizer Inc. (United States)
  • Sanofi (France)
  • GlaxoSmithKline plc (United Kingdom)
  • Novartis AG (Switzerland)
  • Merck & Co., Inc. (United States)
  • Amgen, Inc. (United States)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Sun Pharmaceutical Industries Ltd. (India)
  • AbbVie, Inc. (United States)
  • Mylan N.V. (United States)
Select User Access Type

Key Highlights of Report


May 2023 231 Pages 69 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Cholesterol Lowering Agents Market Quantitative research analysis
Global Cholesterol Lowering Agents Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Cholesterol Lowering Agents market are Pfizer Inc. (United States), Sanofi (France), GlaxoSmithKline plc (United Kingdom), Novartis AG (Switzerland), Merck & Co., Inc. (United States), Amgen, Inc. (United States), Takeda Pharmaceutical Company Limited (Japan), Sun Pharmaceutical Industries Ltd. (India), AbbVie, Inc. (United States) and Mylan N.V. (United States), to name a few.
"Raising health awareness is supporting the growth of cholesterol-lowering agents on a global level " is seen as one of major influencing trends for Cholesterol Lowering Agents Market during projected period 2022-2028.
Statins and Combination segment in Global market to hold robust market share owing to "The increasing cases of mortality rate due to cardiovascular diseases ".

Know More About Global Cholesterol Lowering Agents Market Report?

Have a Query? Click Here

Other Related Reports

Acyclovir Injection Comprehensive Study by Type (Nucleotide Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Others), Application (HIV, Hepatitis, Herpes Simplex Virus, I...
$ 3750
Liposome Assisted Drug Delivery Comprehensive Study by Type (Liposomal Doxorubicin, Liposomal Amphoteracin B, Liposomal Paclitaxel, Others), Application (Fungal Infection Therapy, Cancer and Tumor Th...
$ 3750
Heart Disease Drugs Comprehensive Study by Drug Type (Antihypertensive, Antihyperlipidemic, Anticoagulants, Antiplatelet Drugs, Others), Disease (Hypertension, Hyperlipidemia, Coronary Artery Disease...
$ 3650
Cholesterol Drug Comprehensive Study by Type (Atorvastatin (Lipitor), Fluvastatin (Lescol), Lovastatin, Pitavastatin (Livalo), Pravastatin (Pravachol), Rosuvastatin calcium (Crestor), Simvastatin (Zo...
$ 3750
Smart Pill Dispenser Comprehensive Study by Type (Centralized automated dispensing system (Robots and Carousels), Decentralized automated dispensing system (Pharmacy-based automated dispensing system...
$ 3650
Certolizumab pegol Comprehensive Study by Type (Single-dose Vial, Single-dose Prefilled Syringe), Application (Crohn's Disease, Active Rheumatoid Arthritis, Active Psoriatic Arthritis), Distribution ...
$ 3450